Hengsai Biotechnology
DC Vaccine for Nasopharyngeal Carcinoma [Medium Swelling] Completes First Patient Enrollment for Dosing
357DC Vaccine for Nasopharyngeal Carcinoma [Medium Swelling] Completes First Patient Enrollment for Dosing
View detailsHengsai Bio 2024 Annual Meeting & Spring Tour Special
Gathering of Minds, Building Dreams and Moving Forward
preamble
The dragon is in full bloom, welcoming the spring, and the elites are gathering for the annual event. Looking back to 2023, it is to overcome difficulties and move forward; looking forward to 2024, it is to compete with a hundred boats and oar first. Accompanied by the spring breeze in April, Hengsai Bio held the 2024 Annual Meeting and Spring Tour Group Building Activity in Anji, Zhejiang Province.
Spring Overture
Annual Banquet
On April 12, all the staff started the annual meeting trip in a relaxed and happy atmosphere. Shanghai headquarter and Wuhan clinical team met triumphantly, and kicked off the annual meeting with a feast. The staff members shared their true feelings with each other in a big group of wine, and sang the song of spring after tea and dinner.
Unity
Unlimited Vitality
In the warm spring breeze, the team carried out a series of fun and interactive games. Shiatsu board sports challenge let everyone quickly into the collective, exercise physical and mental, release vitality. Dragons fetch water to test the trust and tacit understanding between team members, the magic pen Ma Liang enhanced the team's coordination ability, you than I guess it is closer to the team's ideological distance. In the laughter, team members improved their understanding of each other, experienced the power of teamwork, and were confident to work together to meet more challenges in the future.
Concentration
Building the Dream
On April 13th, at the company's annual summary meeting, Dr. Liu Huining, Founder and CEO of Hengsai Biologicals, reviewed the significant progress of the company in the past year, thanked the team members for their collaboration and hard work, and shared the company's work plan for the year 2024, which is to focus on the development and industrialization of dendritic cell vaccines and the development and commercialization of dendritic cell vaccines. The company will continue to focus on dendritic cell vaccine development and industrialization.
Co-founder Mr. Cheng Xiangguo reiterated the company's values and explained in depth the corporate vision of gathering the spirit of a hundred rivers, stimulating the potential of cells, empowering healers, and creating a team of grandeur, which further enhanced the team members' sense of identification with the corporate culture.
Heads of R&D, Production, Quality and Clinical Departments summarized the annual review of departmental work one by one, and made plans and prospects for future work.
Looking back, we are proud of the way forward;
Based on the present moment, we work together in the wind and rain, breaking the waves forward;
As we look to the future, we always look forward with enthusiasm and fearlessness;
We believe that Hengsai Bio will ride the waves and sail away.
Springtime is in full bloom.
Enjoy the fjord
The most beautiful April day on earth, not to live up to the spring light and time. After the meeting, we collectively went to the Grand Canyon in northern Zhejiang to get close to nature and relax the mind while breaking through the self.
concluding remarks
The Kaiju is not as far away as the mountains and the seas.
Ride the momentum, not the days and months.
Here's to every dream chaser, the beginning of the end, surging forward;
Here's to Hengsai Biologicals, to the future and to further success!
Related recommendations
-
-
2023 ASH | Hengsai Biotechnology to go to the international academic stage and present the latest research results of hematological oncology
79Hengsai Bio USA - San Diego The 65th Annual Meeting of the American Society of Hematology (ASH) was grandly held in San Diego, USA on December 9-12, 2023. As the largest, most numerous and most influential annual meeting in the field of international hematology, this year's ASH Congress gathered 35,000 specialists and scholars from 109 countries and regions around the world to present their latest achievements, exchange ...
View details -
2025 EHA: Henselbio's KSD-101 DC Vaccine Breakthrough Data Unveiled, Expanding New Boundaries for EBV Hematoma Treatment
41Hengsai BioItaly - Milan The 30th Annual Meeting of the European Hematology Association (EHA 2025) was successfully concluded from June 12 to 15 in Milan, Italy. As a global top event in the field of hematology, EHA gathered the world's top experts, scholars and industrial pioneers to discuss the latest breakthroughs and future direction of blood disease diagnosis and treatment. In this international academic feast, Hengsai Biotechnology, as one of the...
View details -
2025 Annual Meeting and Spring Reunion Special Hengsai Biology
147The snake offered a new chapter, and the elites went to the spring banquet together. At the time when the snake is coiled up and everything is new, all the staff of Hengsai Bio-technology gathered together and held the 2025 Annual Meeting and Annual Summarization Activity in Zhoushan, Zhejiang Province. The team of Hengsai traveled on the waves, refined tacit understanding with collaboration, and cohesion of consensus with laughter, and drew the prelude of the New Year together among the blue sea and golden sand. Breaking through ten thousand hectares of waves, the team went on a journey to the blue sea...
View details
